Vanda Pharmaceuticals Inc.
NASDAQ:VNDABiotechnology
-$0.20 today
- Market cap
- $226.76M
- Beta
- 0.60
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$4.03
Volume 0.95M
Average 1.29M
VNDA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Vanda Pharmaceuticals Inc.NASDAQ: VNDA
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q1 FY2026 research & development of $28.44M fell 20.4% year over year, behind the +14.6% change in trailing-twelve-month research & development. Sequentially, it fell 2.0% from the prior quarter. Over 3 fiscal years it compounded at +8.4% a year.
Context
- Research & development amounted to 50.6% of revenue in FY2025, up 13.1 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -20.4% toward the trailing-twelve-month pace of +14.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 109.27M USD
- Year-over-year change
- +46.8%
- 4-year CAGR
- +9.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 109.27M | +46.8% |
| FY2024 | 2024-12-31 | 74.43M | -3.1% |
| FY2023 | 2023-12-31 | 76.82M | -10.4% |
| FY2022 | 2022-12-31 | 85.77M | +13.8% |
| FY2021 | 2021-12-31 | 75.36M | — |
Research & Development vs competitors
How VNDA compares with its peers on the latest reported figures
- VNDA's LTM Mar 2026 research & development of $101.99M is the 6th highest of the 11 companies compared; the peer median is $113M.
- Its year-over-year change of +14.6% is the 4th highest of 11, against a peer median of -7.2%.
- Research & development amounts to 46.8% of revenue for VNDA, versus a peer median of 1423.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.68B | +22061.7% | +5.1% | — | |
| LTM Mar 2026 | $159.57M | +37.4% | +18.6% | — | |
| LTM Mar 2026 | $143.25M | +11.2% | +28.8% | 2496.5% | |
| LTM Mar 2026 | $129.09M | -32.1% | -16.3% | — | |
| LTM Mar 2026 | $127.75M | -3.1% | +30.4% | 350.1% | |
| LTM Mar 2026 | $101.99M | +14.6% | +8.4% | 46.8% | |
| LTM Mar 2026 | $98.25M | -44.3% | -8.8% | 216.6% | |
| LTM Mar 2026 | $92.92M | +60.8% | +57.0% | — | |
| LTM Mar 2026 | $73.35M | -11.4% | +3.1% | 3638.2% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $30.71M | -36.7% | +16.2% | — |
| LTM Mar 2026 | $19.19M | -29.2% | -8.6% | — | |
| Peer median (excluding VNDA) | $113M | -7.2% | +10.6% | 1423.3% | |
Competitors are the stored peer set for VNDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 268.68M | 254.38M | 192.64M | 198.77M | 216.11M |
| Cost of Revenue | 25.63M | 24.28M | 14.8M | 11.31M | 13.04M |
| Gross Profit | 243.05M | 230.1M | 177.84M | 187.46M | 203.06M |
| Gross Margin | 90.5% | 90.5% | 92.3% | 94.3% | 94.0% |
| Research & Development | 75.36M | 85.77M | 76.82M | 74.43M | 109.27M |
| Selling, General & Admin | 124.05M | 136.49M | 112.88M | 146.41M | 237.95M |
| Operating Expenses | 200.89M | 223.77M | 191.8M | 228.12M | 354.23M |
| Depreciation & Amortization | 2.84M | 2.73M | 3.01M | 8.13M | 11.92M |
| EBITDA | 45.21M | 14.03M | 9.35M | (14.79M) | (126.73M) |
| EBITDA Margin | 16.8% | 5.5% | 4.9% | -7.4% | -58.6% |
| Operating Income | 42.17M | 6.33M | (13.95M) | (40.66M) | (151.17M) |
| Operating Margin | 15.7% | 2.5% | -7.2% | -20.5% | -70.0% |
| Interest Income | 199K | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 199K | 4.97M | 20.29M | 17.74M | 12.52M |
| Income Before Tax | 42.36M | 11.3M | 6.34M | (22.92M) | (138.65M) |
| Pre-Tax Margin | 15.8% | 4.4% | 3.3% | -11.5% | -64.2% |
| Income Tax Expense | 9.21M | 5.03M | 3.83M | (4.02M) | 81.83M |
| Net Income | 33.15M | 6.28M | 2.51M | (18.9M) | (220.47M) |
| Net Margin | 12.3% | 2.5% | 1.3% | -9.5% | -102.0% |
| EPS (Basic) | 0.60 | 0.11 | 0.04 | (0.32) | (3.74) |
| EPS (Diluted) | 0.58 | 0.11 | 0.04 | (0.32) | (3.74) |
| Weighted Avg Shares | 55.55M | 56.46M | 57.38M | 58.15M | 58.93M |
| Weighted Avg Shares (Diluted) | 56.92M | 56.98M | 57.56M | 58.15M | 58.93M |
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
Intrinsic Alpha fair value
Locked
Current Price
$3.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.